Dipeptidyl Peptidase 4 Inhibitors
Glucagon-like Receptor Agonists
Drugs Used in Lower Respiratory Disorders: Overview
Oral Hypoglycemic Agents: Biguanides and Glitazones
Insulin: Dosing Regimen and Adverse Effects
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jan 6, 2026

Intranasal Administration of CNS Therapeutics to Awake Mice
Published on: April 8, 2013
S-Y Li1, H-H Chen2,3,4, C-C Lai5
1From the Department of Otorhinolaryngology, Head and Neck Surgery, Changhua Christian Hospital, Nanhsiau Street, Changhua, Taiwan.
Dipeptidyl peptidase-4 inhibitor (DPP4i) treatment may reduce the risk of chronic rhinosinusitis (CRS) in diabetic patients. This finding suggests a potential benefit of DPP4i for managing CRS in this population.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: